Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MHC class I chain-related proteins A and B (MICA and MICB) are highly polymorphic cell surface glycoproteins encoded within the major histocompatibility complex locus. Unlike classical MHC class I molecules, they do not associate with β2-microglobulin nor present peptides. Instead, they function primarily as stress-induced ligands that activate immune responses by binding to the NKG2D receptor on natural killer cells, γδ T cells, and CD8+ αβ T cells. This interaction serves as a "kill me" signal to cytotoxic lymphocytes when a cell is under stress due to infection or transformation. While their expression is upregulated in many tumor types—making them potential targets for cancer immunotherapy—they are also expressed intracellularly in most normal epithelial tissues with only occasional cell surface localization. This broad tissue distribution presents challenges for selective therapeutic targeting[3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MHC class I chain-related protein A/B (MICA/B).